Michele Cottler‐Fox

High Impact

Professor

UAMS primary UA Little Rock

Also affiliated: University of Maryland, Baltimore (1996–2003); Brigham and Women's Hospital (1998); Centers for Disease Control and Prevention (1992); National Institutes of Health (1974–1998); Oregon State University (1974–1975); The University of Texas MD Anderson Cancer Center (1998); Georgetown University (1988–1992); University of Utah (2008); University of Michigan (1998); University of Arkansas Medical Center (2004–2026); Georgetown University Medical Center (1988–1991); Albert B. Chandler Hospital (1998); Karolinska Institutet (1979–1987); Central Arkansas Veterans Healthcare System (2006–2008); Cancer Research And Biostatistics (2003); National Heart, Lung, and Blood Institute (1995–1997); National Institute of Neurological Disorders and Stroke (1995); Michigan Medicine (1998); Dana-Farber Cancer Institute (1998–2003); National Cancer Institute (1997); National Cancer Institute (1997); National Institute of Allergy and Infectious Diseases (1975); National Cancer Institute (1974–1997); National Institutes of Health Clinical Center (1992–1995); University of Maryland Marlene and Stewart Greenebaum Comprehensive Cancer Center (1996–2003); Georgetown Lombardi Comprehensive Cancer Center (1990–1991); University of Bergen (2013)

42 h-index 209 pubs 6,717 cited

Research Areas

Biomedical Subjects

Links

ORCID Research Group

OverviewAI-generated summary

Michele Cottler‐Fox, a professor at the University of Arkansas for Medical Sciences, has a research focus that includes hematopoietic stem cell transplantation and multiple myeloma treatments. Her work has investigated long-term outcomes of various therapeutic regimens for multiple myeloma, such as maintenance therapy with VRD (bortezomib, lenalidomide, dexamethasone) and the impact of fractionated melphalan transplants with added bortezomib and thalidomide. Cottler‐Fox also examines operational aspects of cell therapy laboratories, including the effects of new collection goals on apheresis processes and the implications of autologous hematopoietic progenitor cell boosts after CAR-T therapy.

Her research extends to cord blood banking, exploring the barriers and facilitators among pregnant women, including specific investigations into Hispanic populations. Additionally, Cottler‐Fox has contributed to understanding thrombotic microangiopathies, identifying predictors of acquired thrombotic thrombocytopenic purpura (aTTP) using HLA-DR-DQ associations and the PLASMIC score. She leads a research group and collaborates with colleagues at the University of Arkansas for Medical Sciences, including Clyde Bailey and Susan Panozzo. Cottler‐Fox is recognized as a highly cited researcher, with an h-index of 42 and over 200 publications.

Metrics

h-index: 42
Publications: 209
Citations: 6,717

Positions

Professor 2000–present

University of Arkansas for Medical Sciences Pathology ORCID

Selected Publications

Post‐transport macroscopic aggregates in a filtered bone marrow harvest bag (2026)

Transfusion DOI OpenAlex
Barriers and facilitators to, and knowledge of, cord blood banking among pregnant Hispanic women at a university obstetric clinic (2026)

DOI OpenAlex
Impact of New Hematopoietic Progenitor Cell Collection Goals on Apheresis and Cell Therapy Laboratory Services (2025)

DOI OpenAlex
AUTOLOGOUS HEMATOPOIETIC PROGENITOR CELL (HPC) BOOSTS AFTER CHIMERIC ANTIGEN RECEPTOR T-CELL (CAR-T) THERAPY: IMPACT ON THE CELL THERAPY LABORATORY AND STORAGE FACILITY (2025)

DOI OpenAlex
SMALL CHANGES, BIG SAVINGS: IMPACT OF HEMATOPOIETIC PROGENITOR CELLS APHERESIS COLLECTION GOALS ON THE CELL THERAPY LAB (2024)

DOI OpenAlex
HLA-DR-DQ associations, combined with PLASMIC score, are reliable predictors of acquired thrombotic thrombocytopenic purpura (aTTP) and aid in differentiating aTTP from other thrombotic microangiopathies (2024)

DOI OpenAlex
Three years of maintenance with VRD in multiple myeloma: results of total therapy IIIB with a 15-year follow-up (2023)

Blood Advances 10 citations DOI OpenAlex
Barriers and facilitators to cord blood banking among pregnant women at a university obstetric clinic (2023)

Transfusion 4 citations DOI OpenAlex
Hybrid cord blood banks may be advantageous for scientific as well as economic reasons (2020)

Cytotherapy DOI OpenAlex
Concepts and Rationale for Using Predictive Algorithms for Hematopoietic Progenitor Cell Apheresis Collection (2019)

Advances and controversies in hematopoietic transplantation and cell therapy DOI OpenAlex
A hands‐on resident umbilical cord blood educational curriculum compared to online education of post‐residency obstetricians: comparison of the volume of collected cord blood units (2019)

Transfusion 1 citation DOI OpenAlex
ADAMTS13 Testing Methodologies and Thrombotic Thrombocytopenic Purpura (TTP): Conflicting Results Can Pose a Clinical Dilemma. (2018)

PubMed 2 citations OpenAlex
M1 and M2 macrophages differentially regulate hematopoietic stem cell self-renewal and ex vivo expansion (2018)

Blood Advances 60 citations DOI OpenAlex
Optia® continuous mononuclear collection (CMNC) system is a safe and efficient system for hematopoietic progenitor cells‐apheresis (HPC‐a) collection and yields a lower product hematocrit (HCT%) than the COBE® spectra system: A retrospective study (2018)

Journal of Clinical Apheresis 27 citations DOI OpenAlex
Complement Regulatory Genetic Mutations in the Setting of Autoimmune Thrombotic Thrombocytopenic Purpura: A Case Series (2017)

Mayo Clinic Proceedings Innovations Quality & Outcomes 9 citations DOI OpenAlex